Metal organic frameworks identified as delivery mechanisms for insoluble drugs

European Pharmaceutical Review | October 04, 2019

New chemical entities are largely insoluble, which creates a significant challenge when formulating new drugs; but scientists have recognised the potential of metal organic frameworks (MOFs) as alternative delivery mechanisms for such drugs. Stable metal organic frameworks are prized for their ability to capture carbon dioxide or harvest atmospheric water, but researchers from the University of Michigan have developed a use for unstable metal organic frameworks: as a system for drug delivery. Ninety percent of drugs in development have dissolving issues – ie, they do not dissolve well or at all in the body, according to a 2012 study. Metal organic frameworks (MOFs) are rigid, porous structures composed of metal linked by organic ligands. While investigating unstable MOFs, U-M chemist Adam Matzger discovered their capability to work as a potential delivery system for insoluble drugs.

Spotlight

Drug diversion incidents are increasing at an alarming rate. With numbers higher than ever before, people still believe that it could never happen within their facility. Choosing to ignore the issue can put both your patients and the facility at risk.

Spotlight

Drug diversion incidents are increasing at an alarming rate. With numbers higher than ever before, people still believe that it could never happen within their facility. Choosing to ignore the issue can put both your patients and the facility at risk.

Related News

PHARMACY MARKET

EMA starts rolling review of CureVac’s COVID-19 vaccine (CVnCoV)

CureVac, EMA | February 18, 2021

The European Medicines Agency (EMA's) Committee for Human Medicinal Products (CHMP) has begun a moving audit of CureVac AG's COVID-19 antibodies, CVnCoV. The survey was started on the grounds that starter research facility contemplates and early clinical preliminary outcomes recommend the immunization triggers the creation of antibodies and insusceptible cells that target SARS-CoV-2, the infection that causes COVID‑19. The survey will successively audit information as it opens up, beginning with the preclinical and beginning stage proof presently submitted. As opposed to a customary advertising authorisation application, in which all information on a medication's or immunization's viability, security and quality and all necessary archives should be prepared toward the beginning of the assessment. Continuous preliminaries are proceeding to assess the immunization's wellbeing, immunogenicity and viability against COVID-19. EMA will assess information from these and other clinical preliminaries as they become accessible. The moving audit will proceed until the CHMP concludes that adequate information is accessible for a conventional showcasing authorisation application. Because of the work attempted in the moving audit, it should take less time than typical to assess such an application. EMA will survey the immunization's consistence with the typical norms for adequacy, wellbeing and drug quality inside the moving audit measure. About CVnCoV CVnCoV is an mRNA vaccine which encodes the SARS-CoV-2 Spike (S) protein. The mRNA sequence is formulated in minute lipid particles to prevent it from being broken down too quickly. When a person receives the vaccine, some of their cells will use the mRNA molecules to temporarily produce the S protein. This activates the person’s immune system, priming it to respond more quickly to a subsequent SARS-CoV-2 infection.

Read More

BUSINESS INSIGHTS

Triastek and Siemens Announced a Strategic Partnership to Advance the Pharmaceutical Industry's Digital Transformation

Triastek, Inc | March 21, 2022

Triastek, Inc. and Siemens Ltd., China, have agreed to collaborate on digital technologies for the worldwide pharmaceutical business. Triastek's industry-leading 3D printing and digital pharmaceutical technologies, combined with Siemens' worldwide experience in automation and digitalization, should result in unique and disruptive pharmaceutical research and production solutions. Pharmaceutical companies have been encouraged to modernize their manufacturing processes by adopting continuous manufacturing processes and digital technologies by regulatory agencies such as the US FDA (Food and Drug Administration), the European Medicines Agency and China's NMPA. Triastek is aggressively applying the continuous manufacturing strategy in combination with new digital technologies to simplify and optimize their production processes and products. When these advances are combined with Siemens' digitalization and automation skills, regulatory agencies will be able to meet their goals of reducing pharmaceutical product quality concerns, lowering manufacturing costs, and increasing patient access to high-quality medications. Triastek and Siemens will collaborate to solve pharmaceutical industry demands and enhance patient outcomes using their respective technology advantages, strengths, and capabilities. Triastek's proprietary pharmaceutical MED® (Melt Extrusion Deposition) 3D printing platform technology for R&D and mass production will accelerate product R&D and facilitate continuous manufacturing approaches, paperless production, real-time product release, equipment, and facility maintenance combined with Siemens' advanced automation and digital technologies. These advances are intended to increase throughput on the manufacturing line while maintaining the greatest product quality. Finally, Triastek wants to build an intelligent pharmaceutical production center in conjunction with Siemens, where virtual laboratories, smart factories, and digital twin technologies will be integrated into every element of pharmaceutical operations. Triastek, founded in 2015, is now in the mass manufacturing and commercial development stages. Triastek announced its Era 2.0 Open Strategy in October 2021, which outlines a goal to market its patented MED® 3D printing technology via partnerships with global pharmaceutical firms and suppliers. Triastek delivers digital product R&D and a unique manufacturing platform based on its Open Strategy and cooperation, allowing business partners to use and integrate Triastek technology into their operations, from early medication discovery through commercial production. "This strategic collaboration has broadened the possibilities of pharmaceutical digitalization. Triastek's MED® 3D printing technology represents a new digital pharmaceutical technology, building the foundation for a digital pharma future. MED® 3D printing represents a novel drug R&D paradigm, from product development through product launch, while introducing new models to manage production and supply. Triastek will make this open platform available to digital technology providers to jointly advance the Pharma 4.0 initiative, serving our greater vision of transforming the pharmaceutical industry's future." Dr. Senping Cheng, Founder, and CEO of Triastek Senior Vice President and General Manager of sales region east of digital industries of Siemens Ltd., China, Mr. Jinsong Zhang, also commented on this partnership: "Siemens' strategic cooperation with Triastek builds win-win cooperation of a digital solution provider leader and a 3D printing pharmaceutical leader. Siemens has rich 3D printing experiences and a full spectrum of digital solutions for manufacturing transformation. I believe the fusion of 3D printing technology with pharmaceutical digitalization establishes a new paradigm, which unifies R&D and production, and advances the end-to-end model from demand to delivery. The partnership will help Triastek to accelerate digital ph.

Read More

CNS Pharmaceuticals Announces US Drug Manufacturing Milestones

CNS Pharmaceuticals | September 03, 2020

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, today provides an update on progress for the U.S. manufacturing of Berubicin, the Company's lead drug candidate, in preparation for upcoming clinical trials. As previously announced, the Company implemented a dual-track drug product manufacturing strategy and engaged U.S.-based Pharmaceutics International, Inc. ("Pii") and Italy-based BSP Pharmaceuticals S.p.A. ("BSP") for the production of Berubicin. By engaging two separate manufacturers on two separate continents, CNS expects to mitigate COVID-19-related delay risks, diversify its supply chain and provide for localized availability of Berubicin.

Read More